Recursion Pharmaceuticals Statistics
Total Valuation
RXRX has a market cap or net worth of $2.16 billion. The enterprise value is $1.58 billion.
Important Dates
The last earnings date was Wednesday, November 5, 2025, before market open.
| Earnings Date | Nov 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
RXRX has 521.26 million shares outstanding. The number of shares has increased by 63.30% in one year.
| Current Share Class | 514.90M |
| Shares Outstanding | 521.26M |
| Shares Change (YoY) | +63.30% |
| Shares Change (QoQ) | +7.10% |
| Owned by Insiders (%) | 3.24% |
| Owned by Institutions (%) | 60.32% |
| Float | 503.68M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 38.01 |
| Forward PS | 25.89 |
| PB Ratio | 1.94 |
| P/TBV Ratio | 3.84 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 36.18 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.60, with a Debt / Equity ratio of 0.08.
| Current Ratio | 4.60 |
| Quick Ratio | 4.40 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -295.84 |
Financial Efficiency
Return on equity (ROE) is -91.06% and return on invested capital (ROIC) is -51.43%.
| Return on Equity (ROE) | -91.06% |
| Return on Assets (ROA) | -42.20% |
| Return on Invested Capital (ROIC) | -51.43% |
| Return on Capital Employed (ROCE) | -57.67% |
| Revenue Per Employee | $54,611 |
| Profits Per Employee | -$894,429 |
| Employee Count | 800 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -149,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -43.44% in the last 52 weeks. The beta is 0.92, so RXRX's price volatility has been similar to the market average.
| Beta (5Y) | 0.92 |
| 52-Week Price Change | -43.44% |
| 50-Day Moving Average | 5.25 |
| 200-Day Moving Average | 5.62 |
| Relative Strength Index (RSI) | 33.44 |
| Average Volume (20 Days) | 42,996,833 |
Short Selling Information
The latest short interest is 128.59 million, so 24.67% of the outstanding shares have been sold short.
| Short Interest | 128.59M |
| Short Previous Month | 126.35M |
| Short % of Shares Out | 24.67% |
| Short % of Float | 25.53% |
| Short Ratio (days to cover) | 1.96 |
Income Statement
In the last 12 months, RXRX had revenue of $43.69 million and -$715.54 million in losses. Loss per share was -$1.78.
| Revenue | 43.69M |
| Gross Profit | -362.49M |
| Operating Income | -717.72M |
| Pretax Income | -715.69M |
| Net Income | -715.54M |
| EBITDA | -640.54M |
| EBIT | -717.72M |
| Loss Per Share | -$1.78 |
Full Income StatementBalance Sheet
The company has $659.84 million in cash and $82.37 million in debt, giving a net cash position of $577.46 million or $1.11 per share.
| Cash & Cash Equivalents | 659.84M |
| Total Debt | 82.37M |
| Net Cash | 577.46M |
| Net Cash Per Share | $1.11 |
| Equity (Book Value) | 1.05B |
| Book Value Per Share | 2.13 |
| Working Capital | 559.00M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$441.17 million and capital expenditures -$6.52 million, giving a free cash flow of -$447.69 million.
| Operating Cash Flow | -441.17M |
| Capital Expenditures | -6.52M |
| Free Cash Flow | -447.69M |
| FCF Per Share | -$0.86 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -1,642.79% |
| Pretax Margin | -1,638.15% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RXRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -63.30% |
| Shareholder Yield | -63.30% |
| Earnings Yield | -33.16% |
| FCF Yield | -20.75% |
Dividend DetailsAnalyst Forecast
The average price target for RXRX is $7.25, which is 75.12% higher than the current price. The consensus rating is "Buy".
| Price Target | $7.25 |
| Price Target Difference | 75.12% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 33.81% |
| EPS Growth Forecast (5Y) | -10.73% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RXRX has an Altman Z-Score of 0.75 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.75 |
| Piotroski F-Score | 2 |
